Back to search
Germline BRCA-mutated HER2-negative Breast Cancer
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Germline BRCA-mutated HER2-negative Breast Cancer trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which Germline BRCA-mutated HER2-negative Breast Cancer trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
This study is an open-label, single-arm, multicenter clinical study. 64 patients with germline BRCA-mutated HER2-negative early breast cancer are planned to be…
This phase II trial studies how well olaparib with cediranib or AZD6738 works in treating patients with germline BRCA mutated breast cancer that has spread to o…
The purpose of this study is to assess whether expression of not only POLQ/Polθ, but also Shieldin complex and/or 53BP1 are correlated with primary and/or acqui…
This study evaluates the efficacy of the combination of olaparib, durvalumab, and fulvestrant for the treatment of patients with ER-positive, HER2-negative, loc…
Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment a…